Singapore markets closed

CERo Therapeutics Holdings, Inc. (CERO)

NasdaqGM - NasdaqGM Delayed price. Currency in USD
Add to watchlist
1.1900+0.0400 (+3.48%)
At close: 04:00PM EDT
1.1708 -0.02 (-1.61%)
After hours: 05:29PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 17.52M
Enterprise value 14.99M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)N/A
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) -0.06
52-week change 3-89.04%
S&P500 52-week change 326.27%
52-week high 312.8000
52-week low 31.1300
50-day moving average 31.9571
200-day moving average 38.1500

Share statistics

Avg vol (3-month) 31.1M
Avg vol (10-day) 3114.53k
Shares outstanding 514.72M
Implied shares outstanding 614.72M
Float 87.05M
% held by insiders 144.47%
% held by institutions 133.40%
Shares short (30 Apr 2024) 468.57k
Short ratio (30 Apr 2024) 40.14
Short % of float (30 Apr 2024) 40.62%
Short % of shares outstanding (30 Apr 2024) 40.47%
Shares short (prior month 28 Mar 2024) 420.59k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-7.20%
Return on equity (ttm)N/A

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA N/A
Net income avi to common (ttm)-2.54M
Diluted EPS (ttm)N/A
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)96.87k
Total cash per share (mrq)0.01
Total debt (mrq)1.55M
Total debt/equity (mrq)N/A
Current ratio (mrq)1.65
Book value per share (mrq)N/A

Cash flow statement

Operating cash flow (ttm)-1.52M
Levered free cash flow (ttm)5.11M